DMRA — Damora Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00Annual cashflow statement for Damora Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -51.8 | -61.6 | -38.3 | -21.4 | -210 |
| Depreciation | |||||
| Non-Cash Items | 6.05 | 6.71 | 5.54 | 5.46 | 185 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -6.62 | 11.9 | -4.37 | -2.67 | 18.4 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -52.3 | -42.9 | -36.9 | -18.6 | -6.73 |
| Capital Expenditures | -0.223 | -0.196 | 0 | — | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -47.8 | 12.6 | 22.3 | 11.7 | -17.4 |
| Acquisition of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -48 | 12.4 | 22.3 | 11.7 | -17.4 |
| Financing Cash Flow Items | 0 | — | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 0 | 0.507 | 2.88 | — | 267 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -101 | -29.8 | -11.3 | -7.29 | 243 |